Skip to main content

Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer

Drugs volume 72, pages 28–36 (2012)Cite this article

Abstract

Non-small cell lung cancer (NSCLC) is a heterogeneous disease, caused by the presence of different clinically relevant molecular subtypes. Genetic mutations are emerging as potential biomarkers of response and treatment selection in patients with NSCLC.

Over the past few years, activating mutations of epidermal growth factor receptor (EGFR) have been recognized as the most important predictor of response to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib and also as a favourable prognostic factor.

The RAS genes, including H-RAS, K-RAS and N-RAS, encode a family of proteins regulating cell growth, differentiation and apoptosis. Mutations in the K-RAS gene, mainly in codons 12 and 13, have been found in 20–30% of NSCLC tumor samples and occur most commonly, but not exclusively, in adenocarcinoma histology and in heavy smokers. In NSCLC, the presence of K-RAS mutations has generally been considered to be associated with worse prognosis and resistance to systemic therapy in the adjuvant as well as the metastatic setting. In early stage NSCLC, the prognostic role of K-RAS mutations has been evaluated in several studies without definitive conclusion. On the other hand, in advanced NSCLC, the presence of K-RAS mutations identifies a subgroup of patients who do not respond to EGFR-TKI therapy but, at the same time, a positive survival effect from EGFR-TKIs cannot be excluded in these patients. Similarly, K-RAS mutational status does not predict benefit from the anti-EGFR monoclonal antibody cetuximab, highlighting the biological difference between lung cancer and colorectal cancer. As a result of the lack of conclusive data, K-RAS mutations do not represent a validated biomarker for the negative selection of patients who are candidates for anti-EGFR therapy. The aim of this article is to review and discuss the data on the prognostic and predictive value of K-RAS mutations in NSCLC.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA Cancer J Clin 2009 Jul 1; 59(4): 225–49

    PubMed  Article  Google Scholar 

  2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 Jun 4; 304(5676): 1497–500

    PubMed  Article  CAS  Google Scholar 

  3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 May 20; 350(21): 2129–39

    PubMed  Article  CAS  Google Scholar 

  4. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U∼A 2004 Sep 7; 101(36): 13306–11

    Article  CAS  Google Scholar 

  5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 Sep 3; 361(10): 947–57

    PubMed  Article  CAS  Google Scholar 

  6. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11(2): 121–8

    PubMed  Article  CAS  Google Scholar 

  7. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or Chemotherapy for Non Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med 2010; 362(25): 2380–8

    PubMed  Article  CAS  Google Scholar 

  8. Lee DH, Park K, Kim JH, et al. Randomized Phase III Trial of Gefitinib versus Docetaxel in Non Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy. Clin Cancer Res 2010 Feb 15; 16(4): 1307–14

    PubMed  Article  CAS  Google Scholar 

  9. Zhou C, Wu Y-L, Chen G, et al. Efficay results from the randomised phase II OPTIMAL (CTNOG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR activating mutation. Ann Oncol 2010 Oct; 21 Suppl. 8: viii5

    Google Scholar 

  10. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11(6): 521–90

    PubMed  Article  CAS  Google Scholar 

  11. Shepherd FA, Douillard J, Fukuoka M, et al. Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. ASCO Meeting Abstracts 2009 Jun 8; 27(15S): 8011

    Google Scholar 

  12. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. The Lancet 2008 Nov 28; 372(9652): 1809–18

    Article  CAS  Google Scholar 

  13. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non Small-Cell Lung Cancer. J Clin Oncol 2008 Sep 10; 26(26): 4244–52

    PubMed  Article  CAS  Google Scholar 

  14. Cufer T, Vrdoljak E, Gaafar R, et al., group obotSs. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anti-Cancer Drugs 2006; 17(4): 401-910.1097/01.cad.0000203381.99490.ab

    PubMed  Article  CAS  Google Scholar 

  15. Dahabreh IJ, Terasawa T, Castaldi PJ, et al. Systematic Review: Anti Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal Cancer. Ann Intern Med 2011 Jan 4; 154(1): 37–49

    PubMed  Article  Google Scholar 

  16. Bos JL. ras Oncogenes in Human Cancer: A Review. Cancer Res 1989 Sep 1; 49(17): 4682–9

    PubMed  CAS  Google Scholar 

  17. Rodenhuis S, van de Wetering ML, Mooi WJ, et al. Mutational Activation of the K-ras Oncogene. N Engl J Med 1987; 317(15): 929–35

    PubMed  Article  CAS  Google Scholar 

  18. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008 Mar 1; 58(2): 71–96

    PubMed  Article  Google Scholar 

  19. Forbes S, Clements J, Dawson E, et al. COSMIC 2005. Br J Cancer 2006; 94(2): 318–22

    PubMed  Article  CAS  Google Scholar 

  20. Riely GJ, Kris MG, Marks JL, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. ASCO Meeting Abstracts 2008 Aug 18; 26(15 Suppl.): 8006

    Google Scholar 

  21. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990 Aug 30; 323(9): 561–5

    PubMed  Article  CAS  Google Scholar 

  22. Nelson HH, Christiani DC, Mark EJ, et al. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999 Dec 1; 91(23): 2032–8

    PubMed  Article  CAS  Google Scholar 

  23. Lu C, Soria JC, Tang X, et al. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 2004 Nov 15; 22(22): 4575–83

    PubMed  Article  Google Scholar 

  24. Marks JL, Broderick S, Zhou Q, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 2008 Feb; 3(2): 111–16

    PubMed  Article  Google Scholar 

  25. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005 Jan 17; 92(1): 131–9

    PubMed  Article  CAS  Google Scholar 

  26. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus Cisplatin vs. Observation in Resected Non Small-Cell Lung Cancer. N Engl J Med 2005; 352(25): 2589–97

    PubMed  Article  CAS  Google Scholar 

  27. Tsao M, Hainaut P, Bourredjem A, et al. LACE-BIO pooled analysis of the prognostic and predictive value of kras mutation in completely resected non-small cell lung cancer (NSCLC). Ann Oncol 2010 Oct; 21 Suppl. 8: viii63

    Google Scholar 

  28. Camps C, Jantus-Lewintre E, Cabrera A, et al. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer 2011 Jun; 72(3): 365–9

    PubMed  Article  Google Scholar 

  29. Kalikaki A, Koutsopoulos A, Hatzidaki D, et al. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS-mutation status. Lung Cancer 2010 Jul; 69(1): 110–5

    PubMed  Article  Google Scholar 

  30. Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006 Oct 15; 12 (20 Pt 1): 6049–55

    PubMed  Article  CAS  Google Scholar 

  31. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > or=70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007 Mar 1; 25(7): 760–6

    PubMed  Article  CAS  Google Scholar 

  32. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005 Mar; 2(3): e73

    PubMed  Article  Google Scholar 

  33. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007 May 15; 13(10): 2890–6

    PubMed  Article  CAS  Google Scholar 

  34. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9(10): 962–72

    PubMed  Article  CAS  Google Scholar 

  35. Mao C, Qiu L-X, Liao R-Y, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies. Lung Cancer 2009; 69(3): 272–8

    PubMed  Article  Google Scholar 

  36. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 Jul 14; 353(2): 123–32

    PubMed  Article  CAS  Google Scholar 

  37. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005 Sep 1; 23(25): 5900–9

    PubMed  Article  CAS  Google Scholar 

  38. Zhu C-Q, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008 Sep 10; 26(26): 4268–75

    PubMed  Article  CAS  Google Scholar 

  39. O’Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011 Aug; 12(8): 795–805

    PubMed  Article  Google Scholar 

  40. Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non Small-Cell Lung Cancer. J Clin Oncol 2010 Feb 20; 28(6): 918–27

    PubMed  Article  CAS  Google Scholar 

  41. Spigel DR, Ervin TJ, Ramlau R, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. ASCO Meeting Abstracts 2011 Jun 9; 29 (15 Suppl.): 7505

    Google Scholar 

  42. Sequist L, Akerley W, Brugger W, et al. Final results from ARQ197-209: A global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ197 versus erlotinib plus placebo in previously treated EGFR-inhibitor naive patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol 2010 Oct; 21 Suppl. 8: viii122

    Google Scholar 

  43. Miller VA, O’Connor P, Soh C, et al., for the ATLAS Investigators. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2009 Jun 18; 27(18S): LBA8002

    Google Scholar 

  44. Douillard J-Y, Shepherd FA, Hirsh V, et al. Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial. J Clin Oncol 2010 Feb 10; 28(5): 744–52

    PubMed  Article  CAS  Google Scholar 

  45. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009 May 2; 373(9674): 1525–31

    PubMed  Article  CAS  Google Scholar 

  46. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non,ÄìSmall-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099. J Clin Oncol 2010 Feb 20; 28(6): 911–17

    PubMed  Article  CAS  Google Scholar 

  47. Mukohara T, Engelman JA, Hanna NH, et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005 Aug 17; 97(16): 1185–94

    PubMed  Article  CAS  Google Scholar 

  48. Danenberg KD, Grimminger PP, Mack PC, et al. KRAS mutations (MTs) in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): Implications for cetuximab therapy. ASCO Meeting Abstracts 2010 Jun 14; 28 (15 Suppl.): 10529

    Google Scholar 

  49. Adjei AA, Mauer A, Bruzek L, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2003 May 1; 21(9): 1760–6

    PubMed  Article  CAS  Google Scholar 

  50. Evans TL, Fidias P, Skarin A, et al. A phase II study of efficacy and tolerability of the farnesyl-protein transferase inhibitor L-778, 123 as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21: 2002 (abstr 1861)

  51. Kim ES, Kies MS, Fossella FV, et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 2005; 104(3): 561–9

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK

    Raffaele Califano

  2. Ospedale Civile di Livorno, Istituto Toscano Tumori, Viale Alfieri 36, 57100, Livorno, Italy

    Lorenza Landi &  Federico Cappuzzo

Authors
  1. Raffaele Califano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lorenza Landi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Federico Cappuzzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Federico Cappuzzo.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Califano, R., Landi, L. & Cappuzzo, F. Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer. Drugs 72, 28–36 (2012). https://doi.org/10.2165/1163012-S0-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/1163012-S0-000000000-00000

Keywords

  • Epidermal Growth Factor Receptor
  • Docetaxel
  • Cetuximab
  • Gefitinib
  • Erlotinib